Research&Development
PDTX MODELs ESTABLISHMENT
KINETO Lab successfully developed the system to establish, archive and maintain Patient Derived Tumor Xenograft (PDTX) models in immunodeficient mice in order to provide hundreds of options for using the best preclinical models for in vivo drug testing
The urge for development of effective anticancer compounds lead to the massive number of drug candidates produced.
These novel compounds are always going through preclinical testing, involving in vivo antitumor activity testing in traditional xenograft models of rodents, which although offering good pharmacokinetical data, are limited due to cell line based background of cell derived xenografts (CDX), and act dramatically different than clinical tumors, lacking the variety of tumor cells typically present in patients. This often results low success rate in clinical trials after promising preclinical studies.
As reportedly 95% of drug candidates entering clinical trials fail, mostly because lack of effect and safety, and we believe that using better models, such as PDTXs, drastically reduce the unnecessary clinical testing cost during drug development.
Patient-derived tumor xenografts, originated directly from clinical tumors, offer a suitable solutions for drug development.
PRESERVES
Properties of the clinical tumor
molecular, morphological and immunohistochemical similarity to clinical disease
Microenvironment and heterogeneity
the structure of the clinical tumor is maintained for several generation of host animals
Metabolism and vascularization
nutritient as well as drug supply is reflected from the patients tumor
Functional activity
the cells in PDTX tumors are alive and functionally active through several generations after serial transplantation
PROVIDES
Solutions to drug R&D
the shift from cell line models to PDTXs provides more sophisticated platform in the preclinical drug development
Clinically relevant model
allowing to study drug efficacy in vivo with more relevant data
Reliability of translational research
using the most reliable preclinical models for in vivo drug testing
Predictability of clinical therapeutic response
predicting better the outcomes in the personalized therapy
The figures show that PDTX tumors are preserving the molecular, morphological and immunohistochemical properties of the clinical tumor, while assessment of a PDTX derived cell line — similarly to other traditional cell line xenografts — comes along with a drastic change both tissue structure and molecular marker pattern.
OUR PDTX PROJECT
We develop PDTX models resembling tumor heterogeneity and tumor microenvironment for better predictability of clinical therapeutic response
BIG VARIETY OF PDTXs
KINETO Lab is collecting clinical samples of various cancer types, establishing and biobanking tumor samples from mice for basic and applied research use.
Read more about PDTX model services
Unique characteristics
Our aim is to collect samples from rare malignancies or metastatic sites as well, in order to provide otherwise hardly accessible disease models and to facilitate metastasis-targeting research.
Here you can find out a list of available PDTX models
WORKFLOW
PDTX ESTABLISHMENT
10+ clinical oncology
centers source
We work in cooperation with multiple oncological centers in Hungary in order to access and collect broad variety of clinical tumor samples.
precisely validated
and documented
Serial xenografting in immunodeficient mice, and biobanking of different outcome samples allows us to provide well characterized PDTX model collection with complete documentation.
PDTX derived cell line
cultures (PDTX-C)
Also we establish PDTX-C from the models for the investigation of similarities and differences between cell cultures and serial xenografting.
WORKFLOW
PDTX UTILIZATION
Based on our PDTX database, we are developing our online interface to see all relevant information about our models, including basic clinical data, results of past assays performed on the model, characterization of the model, and its availability.
In vivo tumor experiments, molecular biology samples, or cell lines are equally reachable in order to optimize the tools for every research needs.
partnership
Our aim
is to use this PDTX model collection bank in collaboration with other research groups interested in cancer drug R&D, tumor phenotype biomarker research, tumor evolution, tumor genetic background, tumor heterogeneity and therapy resistance experiments.
In case you are interested in our PDTX models, for further details please contact us on info@kinetolab.hu
more KINETO Lab
R&D projects
Drug Development
Diagnostics
Antibody
Development
Target Identification